Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A

Background: BAY 94-9027 is an extended half-life recombinant factor VIII (rFVIII) that prevents bleeding in persons with hemophilia A at twice-weekly, 5-day, and 7-day dosing intervals. In rare diseases such as hemophilia, where small populations preclude head-to-head comparisons in randomized contr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Blood Med
Autors principals: Batt, Katharine, Gao, Wei, Ayyagari, Rajeev, Deschaseaux, Céline, Vashi, Parth B, Yao, Zhiwen, Wang, Yao, Kessabi, Sophia, Klamroth, Robert
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592019/
https://ncbi.nlm.nih.gov/pubmed/31417326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S206806
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars